Sina Rosenkranz

Sina Rosenkranz studied medicine at the Universities of Hamburg, Pretoria, Berlin and Campeche, receiving her MD in 2014. She completed her neurology training at the University of Hamburg and conducted her postdoctoral training at the Institute of Neuroimmunology and Multiple Sclerosis (INIMS) at the UKE and the Cardiovascular Research Center at the Massachusetts General Hospital (MGH) and the Harvard Medical School in Boston. Since 2023, she has been the research group leader of the research group „Behavioral intervention in neuroimmunology“ at the INIMS. Since 2025, she has been a consultant neurologist and head of the Multiple Sclerosis (MS) Outpatient Clinic at the UKE. Her scientific work focuses on the neuroprotective potential of exercise and high altitude hypoxia in MS. Within the FOR 5705 her interest lies in the impact of inflammation on hippocampal neurogenesis.

Publications

The MoxFo initiative-Mechanisms of action: Biomarkers in multiple sclerosis exercise studies. Rosenkranz S.C., Ploughman M., Hvid L.G. et al. Mult Scler. 29, 1569-1577 (2023).

Visual function resists early neurodegeneration in the visual system in primary progressive multiple sclerosis. Rosenkranz S.C., Gutmann L., Has Silemek A.C. et al. J Neurol Neurosurg Psychiatry. 94, 924-933 (2023).

Treating sarcoidosis-associated progressive multifocal leukoencephalopathy with infliximab. Rosenkranz S.C., Häußler V., Kolster M. et al. Brain Commun. 4, fcab292 (2022).

Enhancing mitochondrial activity in neurons protects against neurodegeneration in a mouse model of multiple sclerosis. Rosenkranz S.C., Shaposhnykov A.A., Träger S. et al. Elife. 10, e61798 (2021).

Low clinical conversion rate in clinically isolated syndrome patients - diagnostic benefit of McDonald 2010 criteria? Rosenkranz S.C., Kaulen B., Neuhaus A. et al. Eur J Neurol. 25, 247-e9 (2018).

Links

Institute of Neuroimmunology and Multiple Sclerosis

Institution